Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
8 146,83 pts
-0.85%


Last updated : 18/11/2026 - 17h35
🏠 Home   ➤    Stock news

DBV Technologies shares drop 12.5% in one week, among the weakest in the SBF 120

The Châtillon-based biotech closes the session near the bottom of the Paris index, in a European market trending lower. The stock extends a decline that has been ongoing for several days, despite a rebound over one month.


DBV Technologies shares drop 12.5% in one week, among the weakest in the SBF 120

A weekly decline that pushes the stock below its moving averages

The share price of DBV Technologies falls 2.94% to €1.75 and is among the largest decliners in the SBF 120, which drops 0.82%. Over seven days, the loss reaches 12.76%, while the stock remains up 11.61% over one month.

The price is now below its 20-day moving average (MM20) at €1.84 (a gap of 4.89%) and its 50-day moving average (MM50) at €1.89, erasing the rebound seen in early November.

The RSI at 44 remains neutral: the move reflects profit-taking after the monthly rise, not an oversold situation. The €1.57 support, approached at the end of October, remains the nearest level on the downside.

An ongoing FDA review and net short positions at 3.49% of share capital

Declared net short positions reach 3.49% of share capital, spread across five funds, up 0.60 point over thirty days. At this level, a notable portion of the capital remains positioned for a decline, with pressure that has intensified over the past month. This figure reflects a bearish bet, without giving the reasons behind it.

On the fundamentals, when publishing its accounts on October 28, 2026, the company reported a doubt about its going concern, and its short-term financing requirement extends beyond the third quarter of 2027.

Meanwhile, the FDA decision on the Viaskin Peanut patch in children aged 4 to 7 is expected in the fourth quarter of 2026: it is the nearest regulatory milestone for the stock.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours